IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. (IDXX) EPS (diluted)

Alert me on EPS (diluted)

IDEXX Laboratories, Inc.'s EPS (diluted) for fiscal 2025 was $13.08, up 22.6% from $10.67 in fiscal 2024. Over the twelve months to 30 June 2026 it was $14.22. Over the past ten years it has ranged from $2.05 (fiscal 2015) to $13.08 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 5th of 52 Diagnostics & Research companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 $13.08 22.59%
FY2024 $10.67 6.06%
FY2023 $10.06 25.28%
FY2022 $8.03 (6.63%)
FY2021 $8.60 28.17%
FY2020 $6.71 37.22%
FY2019 $4.89 14.79%
FY2018 $4.26 44.90%
FY2017 $2.94 20.49%
FY2016 $2.44 19.02%

Quarterly newest first

Period EPS (diluted) Change
Jun 2026 $4.27 23.05%
Mar 2026 $3.47 12.66%
Dec 2025 $3.08 (9.41%)
Sep 2025 $3.40 (6.34%)
42 more quarters

Against its own ten years

Low $2.05 High $13.08
Ten-year median $6.71
Current reading's percentile 100

EPS (diluted) against peers

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on IDXX